JP7079245B2 - Hcp固有のデバイスを使う患者モニタリングのためのシステムおよび方法 - Google Patents
Hcp固有のデバイスを使う患者モニタリングのためのシステムおよび方法 Download PDFInfo
- Publication number
- JP7079245B2 JP7079245B2 JP2019521113A JP2019521113A JP7079245B2 JP 7079245 B2 JP7079245 B2 JP 7079245B2 JP 2019521113 A JP2019521113 A JP 2019521113A JP 2019521113 A JP2019521113 A JP 2019521113A JP 7079245 B2 JP7079245 B2 JP 7079245B2
- Authority
- JP
- Japan
- Prior art keywords
- transmitter
- sensor
- hcp
- data
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 281
- 238000012544 monitoring process Methods 0.000 title description 35
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 228
- 239000008103 glucose Substances 0.000 claims description 228
- 238000004891 communication Methods 0.000 claims description 208
- 230000004044 response Effects 0.000 claims description 34
- 230000007704 transition Effects 0.000 claims description 26
- 238000001514 detection method Methods 0.000 claims description 14
- 230000003213 activating effect Effects 0.000 claims description 5
- 239000013315 hypercross-linked polymer Substances 0.000 description 420
- 239000012491 analyte Substances 0.000 description 107
- 239000000047 product Substances 0.000 description 57
- 238000013075 data extraction Methods 0.000 description 45
- 230000008569 process Effects 0.000 description 44
- 210000004369 blood Anatomy 0.000 description 38
- 239000008280 blood Substances 0.000 description 38
- 238000003860 storage Methods 0.000 description 37
- 238000005259 measurement Methods 0.000 description 36
- 230000005540 biological transmission Effects 0.000 description 35
- 238000004458 analytical method Methods 0.000 description 30
- 230000006870 function Effects 0.000 description 30
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 30
- 238000012545 processing Methods 0.000 description 30
- 238000001994 activation Methods 0.000 description 27
- 230000004913 activation Effects 0.000 description 26
- 238000012795 verification Methods 0.000 description 23
- 238000003780 insertion Methods 0.000 description 22
- 230000037431 insertion Effects 0.000 description 22
- 238000012806 monitoring device Methods 0.000 description 22
- 238000012546 transfer Methods 0.000 description 22
- 206010012601 diabetes mellitus Diseases 0.000 description 21
- 230000007958 sleep Effects 0.000 description 19
- 230000008901 benefit Effects 0.000 description 18
- 230000033001 locomotion Effects 0.000 description 16
- 230000001960 triggered effect Effects 0.000 description 16
- 102000004877 Insulin Human genes 0.000 description 15
- 108090001061 Insulin Proteins 0.000 description 15
- 238000007906 compression Methods 0.000 description 15
- 230000006835 compression Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000036541 health Effects 0.000 description 15
- 229940125396 insulin Drugs 0.000 description 15
- 230000009471 action Effects 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 230000001133 acceleration Effects 0.000 description 12
- 230000002218 hypoglycaemic effect Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000000853 adhesive Substances 0.000 description 11
- 230000001070 adhesive effect Effects 0.000 description 11
- 238000004422 calculation algorithm Methods 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- 230000000737 periodic effect Effects 0.000 description 10
- 230000008054 signal transmission Effects 0.000 description 10
- 230000000007 visual effect Effects 0.000 description 10
- 208000013016 Hypoglycemia Diseases 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000977 initiatory effect Effects 0.000 description 9
- 238000012384 transportation and delivery Methods 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 7
- 230000002641 glycemic effect Effects 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- -1 radioisotope Substances 0.000 description 6
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 5
- 238000004590 computer program Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000005674 electromagnetic induction Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000012805 post-processing Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 4
- 208000001280 Prediabetic State Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000013500 data storage Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000009499 grossing Methods 0.000 description 4
- 238000009434 installation Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 201000009104 prediabetes syndrome Diseases 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000013144 data compression Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000004753 textile Substances 0.000 description 3
- DIVQKHQLANKJQO-UHFFFAOYSA-N 3-methoxytyramine Chemical compound COC1=CC(CCN)=CC=C1O DIVQKHQLANKJQO-UHFFFAOYSA-N 0.000 description 2
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 102000004452 Arginase Human genes 0.000 description 2
- 108700024123 Arginases Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000003990 capacitor Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000012913 prioritisation Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000004984 smart glass Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- WMYLYYNMCFINGV-CKCBUVOCSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O WMYLYYNMCFINGV-CKCBUVOCSA-N 0.000 description 1
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 1
- UYVVLXVBEQAATF-WAIVXGPNSA-N 1b-Hydroxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)C[C@@H](O)[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 UYVVLXVBEQAATF-WAIVXGPNSA-N 0.000 description 1
- LCZBQMKVFQNSJR-UJPCIWJBSA-N 21-deoxycortisol Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)C[C@@H]2O LCZBQMKVFQNSJR-UJPCIWJBSA-N 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 1
- WYEPBHZLDUPIOD-UHFFFAOYSA-N 4,6-dioxoheptanoic acid Chemical compound CC(=O)CC(=O)CCC(O)=O WYEPBHZLDUPIOD-UHFFFAOYSA-N 0.000 description 1
- KJLPSBMDOIVXSN-UHFFFAOYSA-N 4-[4-[2-[4-(3,4-dicarboxyphenoxy)phenyl]propan-2-yl]phenoxy]phthalic acid Chemical group C=1C=C(OC=2C=C(C(C(O)=O)=CC=2)C(O)=O)C=CC=1C(C)(C)C(C=C1)=CC=C1OC1=CC=C(C(O)=O)C(C(O)=O)=C1 KJLPSBMDOIVXSN-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 1
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 102100026044 Biotinidase Human genes 0.000 description 1
- 108010039206 Biotinidase Proteins 0.000 description 1
- JQJPBYFTQAANLE-UHFFFAOYSA-N Butyl nitrite Chemical compound CCCCON=O JQJPBYFTQAANLE-UHFFFAOYSA-N 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- KJQMOGOKAYDMOR-UHFFFAOYSA-N CC(=C)C=C.CC(=C)C=C Chemical compound CC(=C)C=C.CC(=C)C=C KJQMOGOKAYDMOR-UHFFFAOYSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108010071840 Cytosol nonspecific dipeptidase Proteins 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical class OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 208000033748 Device issues Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010028196 Dihydropteridine Reductase Proteins 0.000 description 1
- 102100022317 Dihydropteridine reductase Human genes 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000002476 Falciparum Malaria Diseases 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 206010053240 Glycogen storage disease type VI Diseases 0.000 description 1
- 239000004866 Hashish Substances 0.000 description 1
- 108010085682 Hemoglobin A Proteins 0.000 description 1
- 102000007513 Hemoglobin A Human genes 0.000 description 1
- 108010085686 Hemoglobin C Proteins 0.000 description 1
- 108010068323 Hemoglobin E Proteins 0.000 description 1
- 108091005880 Hemoglobin F Proteins 0.000 description 1
- 102000016871 Hexosaminidase A Human genes 0.000 description 1
- 108010053317 Hexosaminidase A Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108010056651 Hydroxymethylbilane synthase Proteins 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000883511 Lophophora williamsii Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000940612 Medina Species 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 1
- 201000009976 Plasmodium vivax malaria Diseases 0.000 description 1
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 1
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 239000004783 Serene Substances 0.000 description 1
- 108010016797 Sickle Hemoglobin Proteins 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040860 Skin haemorrhages Diseases 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 102100021436 UDP-glucose 4-epimerase Human genes 0.000 description 1
- 108010075202 UDP-glucose 4-epimerase Proteins 0.000 description 1
- 108010082433 UDP-glucose-hexose-1-phosphate uridylyltransferase Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000005469 Vivax Malaria Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 108010063628 acarboxyprothrombin Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229960003116 amyl nitrite Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- NDGSBJSAXJUQTE-UHFFFAOYSA-N azane;phosphorous acid Chemical compound N.OP(O)O NDGSBJSAXJUQTE-UHFFFAOYSA-N 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 108010047389 hemoglobin D Proteins 0.000 description 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 description 1
- 230000006266 hibernation Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940087973 lomotil Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960002803 methaqualone Drugs 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- OOBHFESNSZDWIU-UHFFFAOYSA-N phenmetrazine Chemical compound CC1NCCOC1C1=CC=CC=C1 OOBHFESNSZDWIU-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 229950009829 prasterone sulfate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940099204 ritalin Drugs 0.000 description 1
- 108010093322 s-formylglutathione hydrolase Proteins 0.000 description 1
- 102000028528 s-formylglutathione hydrolase Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960004673 sulfadoxine Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960005367 tetanus antitoxin Drugs 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000013024 troubleshooting Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- FUTVBRXUIKZACV-UHFFFAOYSA-J zinc;3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate Chemical compound [Zn+2].[N-]1C2=C(C)C(CCC([O-])=O)=C1C=C([N-]1)C(CCC([O-])=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 FUTVBRXUIKZACV-UHFFFAOYSA-J 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A43—FOOTWEAR
- A43B—CHARACTERISTIC FEATURES OF FOOTWEAR; PARTS OF FOOTWEAR
- A43B3/00—Footwear characterised by the shape or the use
- A43B3/34—Footwear characterised by the shape or the use with electrical or electronic arrangements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0004—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0031—Implanted circuitry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14503—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F9/00—Arrangements for program control, e.g. control units
- G06F9/06—Arrangements for program control, e.g. control units using stored programs, i.e. using an internal store of processing equipment to receive or retain programs
- G06F9/44—Arrangements for executing specific programs
- G06F9/451—Execution arrangements for user interfaces
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L67/00—Network arrangements or protocols for supporting network services or applications
- H04L67/01—Protocols
- H04L67/10—Protocols in which an application is distributed across nodes in the network
- H04L67/1097—Protocols in which an application is distributed across nodes in the network for distributed storage of data in networks, e.g. transport arrangements for network file system [NFS], storage area networks [SAN] or network attached storage [NAS]
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L67/00—Network arrangements or protocols for supporting network services or applications
- H04L67/14—Session management
- H04L67/141—Setup of application sessions
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
- H04W12/03—Protecting confidentiality, e.g. by encryption
- H04W12/037—Protecting confidentiality, e.g. by encryption of the control plane, e.g. signalling traffic
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
- H04W12/06—Authentication
- H04W12/065—Continuous authentication
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
- H04W12/06—Authentication
- H04W12/068—Authentication using credential vaults, e.g. password manager applications or one time password [OTP] applications
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
- H04W12/06—Authentication
- H04W12/069—Authentication using certificates or pre-shared keys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/18—General characteristics of the apparatus with alarm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3303—Using a biosensor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3507—Communication with implanted devices, e.g. external control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3569—Range sublocal, e.g. between console and disposable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q2220/00—Business processing using cryptography
- G06Q2220/10—Usage protection of distributed data files
- G06Q2220/14—Requiring a supplemental attachment or input, e.g. a dongle, to open
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/40—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L2209/00—Additional information or applications relating to cryptographic mechanisms or cryptographic arrangements for secret or secure communication H04L9/00
- H04L2209/80—Wireless
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/04—Network architectures or network communication protocols for network security for providing a confidential data exchange among entities communicating through data packet networks
- H04L63/0428—Network architectures or network communication protocols for network security for providing a confidential data exchange among entities communicating through data packet networks wherein the data content is protected, e.g. by encrypting or encapsulating the payload
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/06—Network architectures or network communication protocols for network security for supporting key management in a packet data network
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/08—Network architectures or network communication protocols for network security for authentication of entities
- H04L63/0876—Network architectures or network communication protocols for network security for authentication of entities based on the identity of the terminal or configuration, e.g. MAC address, hardware or software configuration or device fingerprint
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/30—Services specially adapted for particular environments, situations or purposes
- H04W4/38—Services specially adapted for particular environments, situations or purposes for collecting sensor information
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/80—Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/02—Power saving arrangements
- H04W52/0209—Power saving arrangements in terminal devices
- H04W52/0251—Power saving arrangements in terminal devices using monitoring of local events, e.g. events related to user activity
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02D—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN INFORMATION AND COMMUNICATION TECHNOLOGIES [ICT], I.E. INFORMATION AND COMMUNICATION TECHNOLOGIES AIMING AT THE REDUCTION OF THEIR OWN ENERGY USE
- Y02D30/00—Reducing energy consumption in communication networks
- Y02D30/70—Reducing energy consumption in communication networks in wireless communication networks
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Computer Networks & Wireless Communication (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Signal Processing (AREA)
- Computer Security & Cryptography (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Optics & Photonics (AREA)
- Data Mining & Analysis (AREA)
- Anesthesiology (AREA)
- Databases & Information Systems (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Emergency Medicine (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Software Systems (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Theoretical Computer Science (AREA)
- Physiology (AREA)
- Human Computer Interaction (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
Description
出願データシートにおいて特定されているいずれかおよび全ての優先権主張、またはそれらに対するいかなる訂正も、米国特許規則1.57の規定により、参照することによって本明細書に組み込まれる。本出願は、2016年12月27日に出願された米国特許第62/439,342号。前述の出願は、参照することによってその全体が本明細書に組み込まれ、本明細書において明示的に本明細書の一部を構成する。
いくつかの実施形態において、システムは、ホストの分析物の連続測定に提供される。本システムは、ホストの分析物の濃度を連続的に測定するように構成された連続分析物センサと、センサの使用中に連続分析物センサに物理的に接続されるセンサ電子機器モジュールと、を含むことができる。特定の実施形態において、センサ電子機器モジュールは、例えば、未処理のセンサデータ、変換されたセンサデータ、および/または任意の他のセンサデータを含むセンサ情報を生成するために、連続分析物センサによって測定した分析物濃度と関連付けられたデータストリームを処理するように構成された電子機器を含む。センサ電子機器モジュールは、異なる表示デバイスが異なるセンサ情報を受信することができるように、それぞれの表示デバイス用にカスタマイズされたセンサ情報を生成するようにさらに構成されることができる。
特定の実施形態では、1つ以上のアラートがセンサ電子機器モジュールと関連付けられる。例えば、各アラートは、それぞれのアラートをいつトリガーされたのかを示す、1つ以上のアラート条件を含むことができる。例えば、低血糖アラートは、最小血糖値を示すアラート条件を含むことができる。アラート条件はまた、傾向データ等の変換されたセンサデータ、および/または多数の異なるセンサからのセンサデータにも基づくことができる(例えば、アラートは、グルコースセンサおよび温度センサの両方からのセンサデータに基づくことができる)。例えば、低血糖アラートは、アラートをトリガーする前に存在していなければならないホストの血糖値における最小限必要な傾向を示すアラート条件を含むことができる。「傾向」という用語は、本明細書で使用される場合、一般に、例えば連続的グルコースセンサからの較正またはフィルタリングされたデータ等の、経時的に獲得されるデータの何らかの属性を示すデータを指す。傾向は、変換済みのまたは未処理のセンサデータを含む、センサデータ等のデータの振幅、変化率、加速度、方向等を示すことができる。
いくつかの実施形態において、センサ電子機器モジュールは、表示デバイスのリストから表示デバイスを検索するように、および/または該表示デバイスとの無線通信を試みるように構成される。いくつかの実施形態において、センサ電子機器モジュールは、所定の順序および/またはプログラム可能な順序(例えば、等級付けおよび/または段階的増大)で、表示デバイスのリストを検索するように、および/または該表示デバイスとの無線通信を試行するように構成され、例えば、第1の表示デバイスとの通信および/または該第1の表示デバイスへのアラーミングの試行の失敗が、第2の表示デバイスとの通信および/または該第2の表示デバイスへのアラーミングの試行をトリガーする、その他である。例示的な一実施形態では、センサ電子機器モジュールは、(1)デフォルト表示デバイスもしくはカスタム分析物監視デバイス、(2)ホストおよび/もしくはケア提供者へのテキストメッセージ、ホストおよび/もしくはケア提供者への音声メッセージ、および/または911)等の聴覚的および/もしくは視覚的方法を介した携帯電話、(3)タブレット、(4)スマートウォッチもしくはブレスレット、ならびに/または(5)スマートメガネもしくは他のウェアラブル表示デバイス等の表示デバイスのリストを順次使用して、ホストもしくはケア提供者を検索し、かつ警報を試行するように構成される。
図1Aを参照すると、いくつかの実施形態では、分析物センサ10は、連続分析物センサ、例えば、皮下、経皮性の(例えば、経皮的)、または血管内デバイスを含む。いくつかの実施形態において、そのようなセンサまたはデバイスは、複数の断続的血液サンプルを分析することができる。本開示は、グルコースセンサの実施形態を含むが、このような実施形態は、他の分析物にも同様に使用され得る。グルコースセンサは、酵素的、化学的、物理的、電気化学的、分光光度的、偏光測定的、熱量測定的、イオン泳動的、放射測定的、免疫化学的、および同類のものを含む、任意のグルコース測定方法を使用することができる。
図1Aを再度参照すると、分析物センサシステムの態様の実施と関連して使用することができるシステム100が表される。いくつかの事例では、システム100を使用して、本明細書で説明される種々のシステムを実施することができる。実施形態のシステム100は、本開示の特定の態様によれば、分析物センサシステム8と、表示デバイス110、120、130、および140と、を含む。分析物センサシステム8は、例示される実施形態において、センサ電子機器モジュール12と、センサ電子機器モジュール12と関連付けられた連続分析物センサ10と、を含む。センサ電子機器モジュール12は、表示デバイス110、120、130、および140のうちの1つ以上と(例えば、直接的または間接的に)無線通信することができる。実施形態では、システム100は、医療デバイス136およびサーバシステム134も含む。センサ電子機器モジュール12はまた、医療デバイス136およびサーバシステム134と無線通信(例えば、直接的または間接的に)し得る。いくつかの例では、表示デバイス110~140はまた、サーバシステム134および/または医療デバイス136と無線通信し得る。
図6は、本構成の実装が位置付けられることができる方法全体を示すフローチャート500である。この図は、本明細書の残りの部分を通して、そして図5の要素を参照して、より詳細に説明されるものを概要的に説明する。
上述したように、ほとんどのHCPは、セッションの開始時に患者のために送信機を設定するための、またはセッションの終了時に送信機からデータを抽出するためのかなりの時間がない。したがって、そのようなタスクを実行する迅速で便利な方法が非常に望まれている。再び図4を参照すると、HCPアプリケーション429と組み合わせたリーダ装置420は、必要なステップを実行するための特に便利で単純な方法を提供することができる。
1つの特定の例示的な実装では、小型の単一使用の使い捨てセンサ製品には、「スマート」送信機、すなわち上述した平滑化などの1つ以上の処理機能を提供する送信機を設けることができ、そのような専門製品またはユーザのスマート装置などの受信機にデータをプッシュするように構成されることができる。使用後、システム全体、すなわち送信機およびセンサならびに接着パッチは、データ抽出および分析のためにHCPに戻されてもよい。場合によっては、データ抽出は、送信機と受信機との間の接続によって既に行われているであろう。そのような装置は、1回だけ較正されてもよく、または工場較正とともに提供されてもよい。既存のアプリケータ技術を使用してセンサをユーザに設置し、場合によっては送信機をセンサ筐体にスナップ留めすることもできる。そのような技術は、例えば、本出願の譲受人によって所有され、全体を参照することにより本明細書に組み入れられる、「経皮分析物センサ、そのためのアプリケータ、および関連方法」と題される2016年10月20日に出願された米国特許出願第15/298,721号に記載されている。
10 連続分析物センサ
12 センサ電子機器モジュール
100 システム
110、120、130、140 表示デバイス
134 サーバシステム
136 医療デバイス
138 無線アクセスポイント(WAP)
Claims (14)
- 所定期間格納され、留置型グルコースセンサと物理的に係合するように構成され、測定されたグルコース濃度値を表す信号をモバイル装置に送信するように構成された送信機を迅速に起動する方法であって、
HCP装置から前記送信機にウェイクアップコマンドを送信することと、
前記送信機によって、前記留置型グルコースセンサからのセンサ信号を検出することとを備え、
前記ウェイクアップコマンドを受信し、かつ前記送信機によって前記留置型グルコースセンサのセンサ信号が閾値を超えたことを検出した際に、前記送信機は非アクティブ状態からアクティブ状態に遷移する、方法。 - 前記ウェイクアップコマンドを送信することが、近距離無線通信またはBluetooth(登録商標)低エネルギーを使用して実行される、請求項1に記載の方法。
- 前記ウェイクアップコマンドを送信することが、少なくとも部分的に前記送信機を動作させているプロセッサ上のウェイクアップピンに信号を通信することによって実行される、請求項1~2のうちいずれか1項に記載の方法。
- 前記ウェイクアップコマンドを送信することが、前記留置型グルコースセンサによって測定された信号の検出に応答して実行される、請求項1~3のうちいずれか1項に記載の方法。
- センサセッションで使用され、留置型グルコースセンサと物理的に係合するように構成され、測定されたグルコース濃度値を表す信号をモバイル装置に送信するように構成され、送信機が、所定期間のセンサセッションに続いて、アクティブ状態から非アクティブ状態に遷移するように構成された送信機を起動する方法であって、
外部装置から前記送信機にウェイクアップコマンドを送信することと、
前記送信機によって、前記留置型グルコースセンサからのセンサ信号を検出することとを備え、
前記ウェイクアップコマンドを受信し、かつ前記送信機によって前記留置型グルコースセンサのセンサ信号が閾値を超えたことを検出した際に、前記送信機は非アクティブ状態からアクティブ状態に遷移する、方法。 - 前記ウェイクアップコマンドを送信することが、近距離無線通信またはBluetooth(登録商標)低エネルギーを使用して実行される、請求項5に記載の方法。
- さらに、前記送信機に記憶されたデータを前記外部装置にダウンロードすることを備える、請求項5~6のうちいずれか1項に記載の方法。
- 前記ウェイクアップコマンドが、近距離無線通信プロトコルを使用して送信される、請求項7に記載の方法。
- 前記ダウンロードが、近距離無線通信プロトコルを使用して実行される、請求項8に記載の方法。
- 前記ダウンロードが、Bluetooth(登録商標)低エネルギープロトコルを使用して実行される、請求項8に記載の方法。
- 前記外部装置がHCP装置である、請求項7に記載の方法。
- 前記HCP装置が、HCPリーダまたはコントローラまたはHCPスマートフォンである、請求項11に記載の方法。
- 前記外部装置が患者装置である、請求項7に記載の方法。
- 前記患者装置が患者のスマートフォンである、請求項13に記載の方法。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022083075A JP7346658B2 (ja) | 2016-12-27 | 2022-05-20 | Hcp固有のデバイスを使う患者モニタリングのためのシステムおよび方法 |
JP2023143731A JP2023164941A (ja) | 2016-12-27 | 2023-09-05 | Hcp固有のデバイスを使う患者モニタリングのためのシステムおよび方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662439342P | 2016-12-27 | 2016-12-27 | |
US62/439,342 | 2016-12-27 | ||
PCT/US2017/068327 WO2018125841A1 (en) | 2016-12-27 | 2017-12-22 | Systems and methods for patient monitoring using an hcp - specific device |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022083075A Division JP7346658B2 (ja) | 2016-12-27 | 2022-05-20 | Hcp固有のデバイスを使う患者モニタリングのためのシステムおよび方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020516324A JP2020516324A (ja) | 2020-06-11 |
JP2020516324A5 JP2020516324A5 (ja) | 2021-02-12 |
JP7079245B2 true JP7079245B2 (ja) | 2022-06-01 |
Family
ID=62625688
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019521113A Active JP7079245B2 (ja) | 2016-12-27 | 2017-12-22 | Hcp固有のデバイスを使う患者モニタリングのためのシステムおよび方法 |
JP2022083075A Active JP7346658B2 (ja) | 2016-12-27 | 2022-05-20 | Hcp固有のデバイスを使う患者モニタリングのためのシステムおよび方法 |
JP2023143731A Pending JP2023164941A (ja) | 2016-12-27 | 2023-09-05 | Hcp固有のデバイスを使う患者モニタリングのためのシステムおよび方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022083075A Active JP7346658B2 (ja) | 2016-12-27 | 2022-05-20 | Hcp固有のデバイスを使う患者モニタリングのためのシステムおよび方法 |
JP2023143731A Pending JP2023164941A (ja) | 2016-12-27 | 2023-09-05 | Hcp固有のデバイスを使う患者モニタリングのためのシステムおよび方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20180182491A1 (ja) |
EP (2) | EP4342378A3 (ja) |
JP (3) | JP7079245B2 (ja) |
CN (2) | CN110325954B (ja) |
AU (3) | AU2017388066B9 (ja) |
CA (2) | CA3139635A1 (ja) |
WO (1) | WO2018125841A1 (ja) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160019360A1 (en) | 2013-12-04 | 2016-01-21 | Apple Inc. | Wellness aggregator |
US12080421B2 (en) | 2013-12-04 | 2024-09-03 | Apple Inc. | Wellness aggregator |
CN111180040B (zh) | 2014-09-02 | 2023-11-10 | 苹果公司 | 身体活动和健身监视器 |
CN113521710A (zh) | 2015-08-20 | 2021-10-22 | 苹果公司 | 基于运动的表盘和复杂功能块 |
US9939908B2 (en) * | 2015-09-28 | 2018-04-10 | Paypal, Inc. | Multi-device authentication |
AU2017100667A4 (en) | 2016-06-11 | 2017-07-06 | Apple Inc. | Activity and workout updates |
US10736543B2 (en) | 2016-09-22 | 2020-08-11 | Apple Inc. | Workout monitor interface |
JP6766967B2 (ja) * | 2016-12-27 | 2020-10-14 | 株式会社デンソー | マイクロロケーションセンサ通信のためのシステムおよび方法 |
US11877219B2 (en) * | 2017-03-29 | 2024-01-16 | Becton, Dickinson And Company | Systems, apparatuses and methods for device pairing having range control and unintended device coexistence detection |
US10845955B2 (en) | 2017-05-15 | 2020-11-24 | Apple Inc. | Displaying a scrollable list of affordances associated with physical activities |
SE543351C2 (en) * | 2017-06-20 | 2020-12-08 | Festina Lotus S A | Improved nfc arrangement |
JP7029247B2 (ja) * | 2017-08-09 | 2022-03-03 | オムロンヘルスケア株式会社 | ユーザ端末、サーバ装置、及び通信パラメータの設定方法 |
JP6920920B2 (ja) * | 2017-08-09 | 2021-08-18 | オムロンヘルスケア株式会社 | データ送信装置およびデータ受信装置 |
CN109426713B (zh) * | 2017-08-28 | 2022-05-24 | 关楗股份有限公司 | 用于身份核实系统中的造假生物特征过滤装置 |
US20190156270A1 (en) * | 2017-11-18 | 2019-05-23 | Walmart Apollo, Llc | Distributed Sensor System and Method for Inventory Management and Predictive Replenishment |
WO2019200362A1 (en) * | 2018-04-12 | 2019-10-17 | The Regents Of The University Of California | Wearable multi-modal bio-sensing system |
US11317833B2 (en) | 2018-05-07 | 2022-05-03 | Apple Inc. | Displaying user interfaces associated with physical activities |
US11109121B2 (en) | 2018-05-10 | 2021-08-31 | Physio-Control, Inc. | Systems and methods of secure communication of data from medical devices |
US11426101B2 (en) | 2018-07-09 | 2022-08-30 | Verily Life Sciences Llc | Systems and methods for sensors with multimode wireless communications and for enabling NFC communications with a wearable biosensor |
US11038555B2 (en) * | 2018-08-06 | 2021-06-15 | Verily Life Sciences Llc | Systems and methods for enabling NFC communications with a wearable biosensor |
CN108924366B (zh) * | 2018-07-26 | 2021-06-15 | 广州视源电子科技股份有限公司 | 一种低电压的提醒方法、装置、电子设备及存储介质 |
US11457843B2 (en) | 2018-08-03 | 2022-10-04 | Dexcom, Inc. | Systems and methods for communication with analyte sensor electronics |
KR102200139B1 (ko) * | 2018-08-07 | 2021-01-08 | 주식회사 아이센스 | 연속혈당측정기의 동작 제어 장치 |
US11882438B2 (en) * | 2018-10-29 | 2024-01-23 | Zorday IP, LLC | Network-enabled electronic cigarette |
US20220139550A1 (en) * | 2019-03-12 | 2022-05-05 | Harmonize Inc. | Population health platform |
AU2020257427A1 (en) * | 2019-04-18 | 2021-11-11 | Abbott Diabetes Care Inc. | Systems, devices, and methods for handling wireless communications in an analyte monitoring environment |
DK201970532A1 (en) | 2019-05-06 | 2021-05-03 | Apple Inc | Activity trends and workouts |
EP3970145A4 (en) * | 2019-05-17 | 2023-05-24 | Senseonics, Incorporated | VALIDATION OF INTEROPERABILITY IN AN ANALYTE MONITORING SYSTEM |
US11457810B2 (en) * | 2019-05-29 | 2022-10-04 | Dexcom, Inc. | System and method for wireless communication of analyte data |
US11277485B2 (en) | 2019-06-01 | 2022-03-15 | Apple Inc. | Multi-modal activity tracking user interface |
GB2584850A (en) * | 2019-06-17 | 2020-12-23 | Airbus Operations Ltd | Distributing data between devices |
US11957876B2 (en) | 2019-07-16 | 2024-04-16 | Beta Bionics, Inc. | Glucose control system with automated backup therapy protocol generation |
WO2021011697A1 (en) | 2019-07-16 | 2021-01-21 | Beta Bionics, Inc. | Blood glucose control system |
WO2021031057A1 (en) * | 2019-08-19 | 2021-02-25 | Medtrum Technologies Inc. | Sensing device |
EP4021287A4 (en) | 2019-08-30 | 2023-10-04 | TT1 Products, Inc. | BIOMARKER MONITORING FITNESS SYSTEM |
WO2021052986A1 (en) | 2019-09-18 | 2021-03-25 | Ascensia Diabetes Care Holdings Ag | Automatic activation of continuous glucose monitoring (cgm) transmitter |
US20210128831A1 (en) * | 2019-11-05 | 2021-05-06 | Insulet Corporation | Systems and methods for determining placement of wearable drug delivery devices |
KR102303553B1 (ko) * | 2019-11-21 | 2021-09-23 | 주식회사 아이센스 | 연속혈당측정용 신체 부착 장치 |
EP4093460A4 (en) * | 2020-01-21 | 2023-09-27 | Medtrum Technologies Inc. | MEDICAL DEVICE WITH SAFETY VERIFICATION AND METHOD FOR SAFETY VERIFICATION THEREOF |
CA3165055A1 (en) * | 2020-01-30 | 2021-08-05 | Massi Joe E. Kiani | Redundant staggered glucose sensor disease management system |
DK202070613A1 (en) | 2020-02-14 | 2021-10-15 | Apple Inc | User interfaces for workout content |
EP3878491A1 (en) | 2020-03-10 | 2021-09-15 | Ypsomed AG | Medical device packaging with nfc pairing support |
KR102474292B1 (ko) * | 2020-03-23 | 2022-12-06 | 이오플로우(주) | 약액 주입 제어 방법 및 컴퓨터 프로그램 |
US11540751B1 (en) * | 2020-03-25 | 2023-01-03 | Tula Health, Inc. | Device networks for chronic health condition management |
CN111504501A (zh) * | 2020-04-26 | 2020-08-07 | 华中科技大学同济医学院附属协和医院 | 一种便携式温监仪及其体温监测方法 |
WO2021219460A1 (en) * | 2020-04-29 | 2021-11-04 | Shl Medical Ag | Hub device for a portable medical device |
CN111568398A (zh) * | 2020-04-30 | 2020-08-25 | 北京科技大学 | 一种基于体域网的生理信号采集系统 |
EP4142583A4 (en) * | 2020-04-30 | 2024-06-05 | Veracron LLC | WEARABLE ELECTRONIC DEVICES, SYSTEMS AND METHODS FOR COLLECTING PATIENT MOVEMENT DATA AND ASSESSING PATIENT ACTIVITY |
EP4397371A3 (en) | 2020-05-19 | 2024-10-30 | Cybin IRL Limited | Deuterated tryptamine derivatives and methods of use |
US11456075B2 (en) * | 2020-06-05 | 2022-09-27 | Biotronik Se & Co. Kg | Implantable medical device having a coding module |
CN111796235B (zh) * | 2020-06-28 | 2022-10-14 | 司浩天 | 一种使用率较高关口表的评估方法 |
EP4182937A1 (en) * | 2020-07-14 | 2023-05-24 | Ascensia Diabetes Care Holdings AG | Tracking insertion and removal times of a continuous glucose monitoring sensor |
CA3187492A1 (en) * | 2020-07-28 | 2022-02-03 | James Robert KERSHNER | Methods and apparatus for aspects of a dose detection system module for a medication delivery device |
US11284818B2 (en) | 2020-08-31 | 2022-03-29 | TT1 Products, Inc. | Glucose exposure diagnostics and therapeutics related thereto |
TWI746182B (zh) * | 2020-09-24 | 2021-11-11 | 禪譜科技股份有限公司 | 多通道恆電位儀裝置 |
JP2023553294A (ja) * | 2020-11-24 | 2023-12-21 | ノボ・ノルデイスク・エー/エス | 医療ロギング装置用の高速データ送信特徴 |
US20220189603A1 (en) | 2020-12-07 | 2022-06-16 | Beta Bionics, Inc. | Medicament pumps and control systems for managing glucose control therapy data of a subject |
US11938376B2 (en) | 2021-05-15 | 2024-03-26 | Apple Inc. | User interfaces for group workouts |
WO2022245763A1 (en) * | 2021-05-17 | 2022-11-24 | Dexcom, Inc. | Data-stream bridging for sensor transitions |
WO2022271827A1 (en) * | 2021-06-23 | 2022-12-29 | Abbott Diabetes Care Inc. | Medical monitoring systems with cloud communication interface |
EP4360104A1 (en) * | 2021-06-23 | 2024-05-01 | Abbott Diabetes Care, Inc. | Medical monitoring systems with cloud communication interface |
WO2023280820A1 (en) * | 2021-07-05 | 2023-01-12 | Nordsjællands Hospital - Hillerød | System, server device, and electronic device, and related methods for disease monitoring and/or handling |
US20230022816A1 (en) * | 2021-07-23 | 2023-01-26 | Fresenius Medical Care Holdings Inc. | New language transfer |
WO2023031047A1 (en) * | 2021-08-30 | 2023-03-09 | Implantica Patent Ltd | A device for secure communication with and operation of an implant |
USD1004777S1 (en) | 2021-09-01 | 2023-11-14 | TT1 Products, Inc. | Wrist reader |
CN113744591B (zh) * | 2021-09-06 | 2023-03-14 | 张朔 | 一种神经中枢病理反射检测训练装置 |
US11889570B1 (en) * | 2021-09-22 | 2024-01-30 | Amazon Technologies, Inc. | Contextual device pairing |
WO2023046480A1 (en) * | 2021-09-24 | 2023-03-30 | Biotronik Se & Co. Kg | System and method for identifying an active medical implant |
CA3206301A1 (en) | 2021-09-28 | 2023-04-06 | George Albert Mansfield Iii | Microneedle enclosure and applicator device for microneedle array based continuous analyte monitoring device |
CN118401165A (zh) * | 2021-12-17 | 2024-07-26 | 德克斯康公司 | 分析物传感器部署测试 |
USD1033641S1 (en) | 2021-12-17 | 2024-07-02 | Biolinq Incorporated | Microneedle array sensor applicator device |
CN114374946B (zh) * | 2022-03-17 | 2022-06-21 | 苏州百孝医疗科技有限公司 | 用于分析物浓度数据监测系统的通信方法及装置 |
US11977729B2 (en) | 2022-06-05 | 2024-05-07 | Apple Inc. | Physical activity information user interfaces |
US11896871B2 (en) | 2022-06-05 | 2024-02-13 | Apple Inc. | User interfaces for physical activity information |
CN114705844B (zh) * | 2022-06-07 | 2022-09-23 | 黑龙江中医药大学 | 一种用于心梗诊断的肌红蛋白检测试剂盒 |
US12070313B2 (en) * | 2022-07-05 | 2024-08-27 | Biolinq Incorporated | Sensor assembly of a microneedle array-based continuous analyte monitoring device |
CN114980363B (zh) * | 2022-07-27 | 2024-03-19 | 荣耀终端有限公司 | 一种蓝牙回连方法及其相关装置 |
JP2024047363A (ja) * | 2022-09-26 | 2024-04-05 | アークレイ株式会社 | 測定装置、測定システム、測定方法、及び測定プログラム |
US20240108238A1 (en) * | 2022-10-03 | 2024-04-04 | Know Labs, Inc. | Analyte sensors with position adjustable transmit and/or receive components |
US20240144715A1 (en) * | 2022-10-26 | 2024-05-02 | Know Labs, Inc. | System and method for identity-based analyte detection and analysis |
WO2024175627A1 (en) * | 2023-02-24 | 2024-08-29 | Fresenius Vial Sas | Method of operation of an infusion pump for operation in a wireless communication network, infusion pump and communication module |
CN118075920B (zh) * | 2024-04-18 | 2024-07-02 | 合肥综合性国家科学中心人工智能研究院(安徽省人工智能实验室) | 蓝牙设备入网方法、系统、蓝牙网关及存储介质 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012516735A (ja) | 2009-02-04 | 2012-07-26 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 血糖コントロールのための情報を提供するための医療システム及び方法 |
JP2015506733A (ja) | 2011-12-15 | 2015-03-05 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | 生理学的データの解釈改善および生理学的状態管理情報の提示改善のためのシステム |
JP2015533093A (ja) | 2012-09-17 | 2015-11-19 | アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. | 検体監視システムで有害な状態の通知を提供するための方法および装置 |
US20150341438A1 (en) | 2014-05-21 | 2015-11-26 | Abbott Diabetes Care Inc. | Management of multiple devices within an analyte monitoring environment |
JP2015211827A (ja) | 2014-05-05 | 2015-11-26 | コヴィディエン リミテッド パートナーシップ | 動力式外科手術器具のためのウェイクアップシステムおよび方法 |
JP2016005585A (ja) | 2009-08-31 | 2016-01-14 | アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. | 通信装置 |
JP2016518881A (ja) | 2013-03-15 | 2016-06-30 | アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. | 医療デバイスデータ処理方法及びシステム、並びに医療デバイスデータ通信方法及びシステム |
JP2016532465A (ja) | 2013-06-25 | 2016-10-20 | ライフスキャン・スコットランド・リミテッド | 少なくとも1つのソーシャルネットワークと通信する生理学的監視システム |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US6081736A (en) | 1997-10-20 | 2000-06-27 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems adapted for long term use |
US6119028A (en) | 1997-10-20 | 2000-09-12 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces |
US6579690B1 (en) | 1997-12-05 | 2003-06-17 | Therasense, Inc. | Blood analyte monitoring through subcutaneous measurement |
US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
GB9805896D0 (en) * | 1998-03-20 | 1998-05-13 | Eglise David | Remote analysis system |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6424847B1 (en) | 1999-02-25 | 2002-07-23 | Medtronic Minimed, Inc. | Glucose monitor calibration methods |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7460898B2 (en) | 2003-12-05 | 2008-12-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US20070208245A1 (en) | 2003-08-01 | 2007-09-06 | Brauker James H | Transcutaneous analyte sensor |
US8060173B2 (en) | 2003-08-01 | 2011-11-15 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8845536B2 (en) | 2003-08-01 | 2014-09-30 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8233959B2 (en) | 2003-08-22 | 2012-07-31 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
WO2005051170A2 (en) | 2003-11-19 | 2005-06-09 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US8532730B2 (en) | 2006-10-04 | 2013-09-10 | Dexcom, Inc. | Analyte sensor |
EP2316331B1 (en) | 2003-12-09 | 2016-06-29 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US10806404B2 (en) * | 2004-03-05 | 2020-10-20 | Health Outcomes Sciences, Inc. | Systems and methods for utilizing wireless physiological sensors |
US7831828B2 (en) * | 2004-03-15 | 2010-11-09 | Cardiac Pacemakers, Inc. | System and method for securely authenticating a data exchange session with an implantable medical device |
US9044199B2 (en) | 2004-07-13 | 2015-06-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
EP3111832B1 (en) * | 2004-07-13 | 2023-12-27 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7890180B2 (en) * | 2004-08-09 | 2011-02-15 | Cardiac Pacemakers, Inc. | Secure remote access for an implantable medical device |
US20070231209A1 (en) * | 2006-04-03 | 2007-10-04 | Cosentino Daniel L | Test strip calibration system for a glucose meter, and method |
WO2007120381A2 (en) | 2006-04-14 | 2007-10-25 | Dexcom, Inc. | Analyte sensor |
US7764798B1 (en) * | 2006-07-21 | 2010-07-27 | Cingular Wireless Ii, Llc | Radio frequency interference reduction in connection with mobile phones |
US8591455B2 (en) | 2008-02-21 | 2013-11-26 | Dexcom, Inc. | Systems and methods for customizing delivery of sensor data |
US20100125183A1 (en) * | 2008-11-17 | 2010-05-20 | Honeywell International Inc. | System and method for dynamically configuring functionality of remote health monitoring device |
WO2011041463A2 (en) * | 2009-09-30 | 2011-04-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
EP3744249A1 (en) * | 2010-10-27 | 2020-12-02 | Dexcom, Inc. | Continuous analyte monitor data recording device operable in a blinded mode |
CN102012390A (zh) * | 2010-11-15 | 2011-04-13 | 普林斯顿医疗科技(珠海)有限公司 | 无线多功能连续葡萄糖监测系统 |
US20120222129A1 (en) * | 2011-02-24 | 2012-08-30 | Cidway Technologies, Ltd. | System and method for secure mobile application download |
EP3906842A1 (en) * | 2011-07-26 | 2021-11-10 | Glysens Incorporated | Tissue implantable sensor with hermetically sealed housing |
US9788354B2 (en) * | 2013-03-14 | 2017-10-10 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US9830673B2 (en) * | 2013-04-26 | 2017-11-28 | Roche Diabetes Care, Inc. | System portal control for a diabetes management system |
AU2014260023B2 (en) * | 2013-04-30 | 2018-12-06 | Abbott Diabetes Care Inc. | Systems, devices, and methods for energy efficient electrical device activation |
WO2015066051A2 (en) * | 2013-10-31 | 2015-05-07 | Dexcom, Inc. | Adaptive interface for continuous monitoring devices |
EP4404210A3 (en) * | 2013-12-27 | 2024-10-16 | Abbott Diabetes Care Inc. | Application interface and display control in an analyte monitoring environment |
EP3092588A1 (en) * | 2014-01-08 | 2016-11-16 | Medicom Innovation Partner a/s | Medical device system and method for establishing wireless communication |
CN104055525A (zh) * | 2014-06-20 | 2014-09-24 | 中国科学院苏州生物医学工程技术研究所 | 植入式低功耗无线血糖监测仪 |
EP3204880B1 (en) * | 2014-10-06 | 2024-06-05 | Dexcom, Inc. | System and method for data analytics and visualization |
US10073976B2 (en) * | 2014-10-24 | 2018-09-11 | Samsung Electronics Co., Ltd. | Application executing method and device, and recording medium thereof |
US10410538B2 (en) * | 2015-05-07 | 2019-09-10 | Dexcom, Inc. | System and method for educating users, including responding to patterns |
EP3091459B1 (en) * | 2015-05-07 | 2020-06-24 | Sorin CRM SAS | Systems and methods for wireless communication with implantable and body-worn devices |
US9999025B2 (en) * | 2016-03-08 | 2018-06-12 | Verily Life Sciences Llc | Beacon using an FBAR-based oscillator |
-
2017
- 2017-12-22 CN CN201780064997.9A patent/CN110325954B/zh active Active
- 2017-12-22 CA CA3139635A patent/CA3139635A1/en active Pending
- 2017-12-22 CA CA3041339A patent/CA3041339A1/en not_active Abandoned
- 2017-12-22 WO PCT/US2017/068327 patent/WO2018125841A1/en unknown
- 2017-12-22 CN CN202310528521.3A patent/CN116548962A/zh active Pending
- 2017-12-22 EP EP23214855.1A patent/EP4342378A3/en active Pending
- 2017-12-22 JP JP2019521113A patent/JP7079245B2/ja active Active
- 2017-12-22 EP EP17889204.8A patent/EP3563224B1/en active Active
- 2017-12-22 US US15/853,493 patent/US20180182491A1/en not_active Abandoned
- 2017-12-22 AU AU2017388066A patent/AU2017388066B9/en active Active
-
2021
- 2021-01-07 US US17/144,017 patent/US20210142912A1/en active Pending
- 2021-05-12 AU AU2021203005A patent/AU2021203005B2/en active Active
-
2022
- 2022-05-20 JP JP2022083075A patent/JP7346658B2/ja active Active
-
2023
- 2023-09-05 JP JP2023143731A patent/JP2023164941A/ja active Pending
- 2023-10-12 AU AU2023248147A patent/AU2023248147A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012516735A (ja) | 2009-02-04 | 2012-07-26 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 血糖コントロールのための情報を提供するための医療システム及び方法 |
JP2016005585A (ja) | 2009-08-31 | 2016-01-14 | アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. | 通信装置 |
JP2015506733A (ja) | 2011-12-15 | 2015-03-05 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | 生理学的データの解釈改善および生理学的状態管理情報の提示改善のためのシステム |
JP2015533093A (ja) | 2012-09-17 | 2015-11-19 | アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. | 検体監視システムで有害な状態の通知を提供するための方法および装置 |
JP2016518881A (ja) | 2013-03-15 | 2016-06-30 | アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. | 医療デバイスデータ処理方法及びシステム、並びに医療デバイスデータ通信方法及びシステム |
JP2016532465A (ja) | 2013-06-25 | 2016-10-20 | ライフスキャン・スコットランド・リミテッド | 少なくとも1つのソーシャルネットワークと通信する生理学的監視システム |
JP2015211827A (ja) | 2014-05-05 | 2015-11-26 | コヴィディエン リミテッド パートナーシップ | 動力式外科手術器具のためのウェイクアップシステムおよび方法 |
US20150341438A1 (en) | 2014-05-21 | 2015-11-26 | Abbott Diabetes Care Inc. | Management of multiple devices within an analyte monitoring environment |
Also Published As
Publication number | Publication date |
---|---|
WO2018125841A8 (en) | 2018-09-27 |
US20210142912A1 (en) | 2021-05-13 |
EP3563224A4 (en) | 2020-07-01 |
EP3563224B1 (en) | 2023-12-20 |
EP4342378A2 (en) | 2024-03-27 |
US20180182491A1 (en) | 2018-06-28 |
CA3041339A1 (en) | 2018-07-05 |
JP7346658B2 (ja) | 2023-09-19 |
JP2022119866A (ja) | 2022-08-17 |
CA3139635A1 (en) | 2018-07-05 |
AU2017388066A1 (en) | 2019-05-16 |
CN110325954A (zh) | 2019-10-11 |
EP3563224A1 (en) | 2019-11-06 |
WO2018125841A1 (en) | 2018-07-05 |
AU2017388066B2 (en) | 2021-03-25 |
AU2021203005B2 (en) | 2023-07-20 |
JP2020516324A (ja) | 2020-06-11 |
AU2023248147A1 (en) | 2023-11-02 |
CN116548962A (zh) | 2023-08-08 |
AU2017388066B9 (en) | 2021-04-01 |
EP4342378A3 (en) | 2024-05-29 |
JP2023164941A (ja) | 2023-11-14 |
AU2021203005A1 (en) | 2021-06-10 |
CN110325954B (zh) | 2023-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7079245B2 (ja) | Hcp固有のデバイスを使う患者モニタリングのためのシステムおよび方法 | |
US11471052B2 (en) | System and method for wireless communication of analyte data | |
KR102632431B1 (ko) | 약물 전달 기기에의 디스플레이 및 제공을 위한 cgm-기반 볼러스 계산기에 대한 시스템 및 방법 | |
JP2021176572A (ja) | 分析物値の伝送及び連続的監視のためのシステム及び方法 | |
US20230089907A1 (en) | System and method for communication of analyte data | |
JP2019513061A (ja) | 表示デバイス及びセンサ電子機器ユニットの通信のためのシステム及び方法 | |
CN117897085A (zh) | 用于连续分析物监测和传感器系统的技术支持的系统和方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201221 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201221 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220125 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220425 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220520 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7079245 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |